<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129575">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02028676</url>
  </required_header>
  <id_info>
    <org_study_id>G0300400</org_study_id>
    <secondary_id>24791884</secondary_id>
    <secondary_id>G0300400</secondary_id>
    <nct_id>NCT02028676</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa</brief_title>
  <acronym>ARROW</acronym>
  <official_title>A Randomised Trial of Monitoring Practice and Induction Maintenance Drug Regimens in the Management of Antiretroviral Therapy in Children With HIV Infection in Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department for International Development, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical Research Council</source>
  <oversight_info>
    <authority>Uganda: National Council for Science and Technology</authority>
    <authority>Uganda: National Drug Authority</authority>
    <authority>Zimbabwe: Medical Research Council</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The two original objectives were to determine in HIV-infected children initiating
      antiretroviral therapy (ART):

        1. Whether clinically driven monitoring (CDM) will have a similar outcome in terms of
           disease progression or death as routine laboratory and clinical monitoring (LCM) for
           toxicity (haematology/biochemistry) and efficacy (CD4)?

        2. Whether induction with four drugs from two ART classes followed by maintenance with
           three drugs after 36 weeks be more effective than a continuous non-nucleoside reverse
           transcriptase inhibitors (NNRTI)-based triple drug regimen in terms of CD4 and clinical
           outcome?

           Two secondary objectives were to determine

        3. Whether changing from twice daily lamivudine+abacavir to once daily lamivudine+abacavir
           after 48 weeks on ART will have a similar outcome in terms of virological suppression
           and will result in improvements in adherence to ART?

        4. Whether stopping daily cotrimoxazole prophylaxis in children over 3 years of age who
           have been on ART for at least 96 weeks has a similar outcome in terms of
           hospitalisation or death as continuing daily cotrimoxazole?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ARROW (AntiRetroviral Research fOr Watoto) protocol describes an open-label randomised
      trial primarily evaluating two strategic approaches for management of antiretroviral therapy
      (ART) in 1200 symptomatic HIV-infected infants and children initiating ART following WHO
      guidelines in Uganda and Zimbabwe. The first strategy compares clinically driven monitoring
      (CDM) with laboratory plus clinical monitoring (LCM). In both groups, tests for toxicity
      (standard haematology and biochemistry panels) and efficacy (lymphocyte subsets including
      CD4 count) will be done every 12 weeks. In LCM, all results will be returned for patient
      management. In CDM, physicians may request results from routine haematology/biochemistry
      panels if needed for clinical management, but results will not be returned routinely, and
      lymphocyte subsets will never be returned. Extra laboratory tests may be requested outside
      of the scheduled visits at any time in either group (except for lymphocyte subsets in CDM).
      The second strategy compares a continuous WHO-recommended first-line ART three-drug
      two-class regimen, comprising two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) plus
      one Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), with induction with four drugs
      (two classes) for 36 weeks followed by maintenance with three drugs. After at least 36 and
      96 weeks on ART respectively, two further randomisations will assess simplification
      strategies which could improve long-term ART adherence (i) once versus twice daily
      lamivudine+abacavir NRTI drugs (ii) stopping versus continuing daily cotrimoxazole
      prophylaxis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>LCM vs CDM: Time to disease progression to a new WHO stage 4 event or death</measure>
    <time_frame>Median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>LCM vs CDM: Time to first grade 3 or 4 adverse event (AE), not solely related to HIV</measure>
    <time_frame>Median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Induction ART: Change from baseline in CD4% 72 weeks after ART initiation</measure>
    <time_frame>Baseline, 72 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Induction ART: Time to first grade 3 or 4 adverse event (AE), not solely related to HIV</measure>
    <time_frame>Median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Once daily abacavir+lamivudine: Suppressed HIV RNA viral load 48 weeks after randomisation</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured retrospectively on stored plasma specimens: due to low stored volumes from some children, samples had to be diluted and therefore a threshold of &lt;80 copies/ml was used to indicate suppression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Once daily abacavir+lamivudine: Time to first grade 3 or 4 adverse event (AE), not solely related to HIV, judged definitely/probably or uncertain whether related to lamivudine or abacavir</measure>
    <time_frame>Median 2 years (from once vs twice daily randomization to 16 March 2012; maximum 2.6 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cotrimoxazole: Time to first hospitalisation or death</measure>
    <time_frame>Median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cotrimoxazole: Time to first grade 3 or 4 adverse event (AE), not solely related to HIV</measure>
    <time_frame>Median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Induction ART: Change from baseline in CD4% to 144 weeks from ART initiation</measure>
    <time_frame>Baseline, 144 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM, Induction ART: Time to first new WHO stage 3 or 4 event or death</measure>
    <time_frame>Median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM, Induction ART: Time to first new or recurrent WHO stage 3 or 4 event or death</measure>
    <time_frame>Median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction ART: Time to first new WHO stage 4 event or death</measure>
    <time_frame>Median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM, Induction ART: time to all-cause mortality</measure>
    <time_frame>Median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM, Induction ART: Weight-for-age z-score</measure>
    <time_frame>Mean change from baseline over median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM, Induction ART: height-for-age Z-score</measure>
    <time_frame>Median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM, Induction ART: body mass index-for-age Z-score</measure>
    <time_frame>Mean change from baseline over median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM: change from baseline in CD4% to week 72</measure>
    <time_frame>Baseline, week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM: change from baseline in CD4% to week 144</measure>
    <time_frame>Baseline, week 144</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM, Induction ART: change from baseline in absolute CD4 to week 72</measure>
    <time_frame>Baseline, week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM, Induction ART: change from baseline in absolute CD4 to week 144</measure>
    <time_frame>Baseline, week 144</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: Time to first grade 3 or 4 adverse event (AE), not solely related to HIV</measure>
    <time_frame>Median 2 years (from once vs twice daily randomization to 16 March 2012; maximum 2.6 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM, Induction ART: Time to first grade 3 or 4 adverse event definitely/probably or uncertainly related to ART</measure>
    <time_frame>Median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM, Induction ART: Time to first serious adverse events not solely related to HIV</measure>
    <time_frame>Median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM, Induction ART: Time to first ART-modifying adverse event</measure>
    <time_frame>Median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM, Induction ART: Time to cessation of first-line regimen for clinical/immunological failure</measure>
    <time_frame>Median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDM vs LCM, Induction ART: Suppression of HIV RNA viral load 72 weeks after baseline</measure>
    <time_frame>72 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDM vs LCM, Induction ART: Suppression of HIV RNA viral load 144 weeks after baseline</measure>
    <time_frame>144 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCM vs CDM, Induction ART: Adherence to ART as measured by self-reported questionnaire (missing any pills in the last 4 weeks)</measure>
    <time_frame>Median 4 years (from randomization to 16 March 2012; maximum 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: Suppression of HIV RNA viral load 96 weeks after randomisation</measure>
    <time_frame>96 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: change from baseline in CD4% to week 48</measure>
    <time_frame>Randomisation to once vs twice daily, week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: change from baseline in CD4% to week 96</measure>
    <time_frame>Randomisation to once vs twice daily, week 96</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: change from baseline in absolute CD4 to week 48</measure>
    <time_frame>Randomisation to once vs twice daily, week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: change from baseline in absolute CD4 to week 96</measure>
    <time_frame>Randomisation to once vs twice daily, week 96</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: Time to first clinical and smear positive malaria</measure>
    <time_frame>Median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diagnostic positive by either microscopy (thick film) or rapid diagnostic test (RDT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: time to first severe pneumonia</measure>
    <time_frame>Median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: time to first WHO stage 3 severe recurrent pneumonia or diarrhoea</measure>
    <time_frame>Median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: Time to first new WHO stage 3 or 4 event or death</measure>
    <time_frame>Median 2 years (from randomization to 16 March 2012; maximum 2.6 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: Time to first new WHO stage 3 or 4 event or death</measure>
    <time_frame>Median 2 years (from randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: Time to first new or recurrent WHO stage 3 or 4 event or death</measure>
    <time_frame>Median 2 years (from randomization to 16 March 2012; maximum 2.6 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: Time to first new or recurrent WHO stage 3 or 4 event or death</measure>
    <time_frame>Median 2 years (from randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: Time to first new WHO stage 4 event or death</measure>
    <time_frame>Median 2 years (from randomization to 16 March 2012; maximum 2.6 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: Time to first new WHO stage 4 event or death</measure>
    <time_frame>Median 2 years (from randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: time to all-cause mortality</measure>
    <time_frame>Median 2 years (from randomization to 16 March 2012; maximum 2.6 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: time to all-cause mortality</measure>
    <time_frame>Median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: Weight-for-age z-score</measure>
    <time_frame>Mean change from baseline over median 2 years (from once vs twice daily randomization to 16 March 2012; maximum 2.6 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: Weight-for-age z-score</measure>
    <time_frame>Mean change from baseline over median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: Height-for-age z-score</measure>
    <time_frame>Mean change from baseline over median 2 years (from once vs twice daily randomization to 16 March 2012; maximum 2.6 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: Height-for-age z-score</measure>
    <time_frame>Mean change from baseline over median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: body mass index-for-age Z-score</measure>
    <time_frame>Mean change from baseline over median 2 years (from once vs twice daily randomization to 16 March 2012; maximum 2.6 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: body mass index-for-age Z-score</measure>
    <time_frame>Mean change from baseline over median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: change from baseline in CD4% to week 72</measure>
    <time_frame>Baseline, week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: change from baseline in CD4% to week 72</measure>
    <time_frame>Baseline, week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction ART: change from baseline in absolute CD4 to week 72</measure>
    <time_frame>Baseline, week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: change from baseline in absolute CD4 to week 72</measure>
    <time_frame>Baseline, week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: change from baseline in absolute CD4 to week 72</measure>
    <time_frame>Baseline, week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: Time to first grade 3 or 4 adverse event definitely/probably or uncertainly related to ART</measure>
    <time_frame>Median 2 years (from once vs twice daily randomization to 16 March 2012; maximum 2.6 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: Time to first grade 3 or 4 adverse event definitely/probably or uncertainly related to ART</measure>
    <time_frame>Median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: Time to first serious adverse events not solely related to HIV</measure>
    <time_frame>Median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: Time to first serious adverse events not solely related to HIV</measure>
    <time_frame>Median 2 years (from once vs twice daily randomization to 16 March 2012; maximum 2.6 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: Time to first ART-modifying adverse event</measure>
    <time_frame>Median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: Time to first ART-modifying adverse event</measure>
    <time_frame>Median 2 years (from once vs twice daily randomization to 16 March 2012; maximum 2.6 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotrimoxazole: Adherence to ART as measured by self-reported questionnaire (missing any pills in the last 4 weeks)</measure>
    <time_frame>Mean over median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Once daily abacavir+lamivudine: Adherence to ART as measured by self-reported questionnaire (missing any pills in the last 4 weeks)</measure>
    <time_frame>Mean over median 2 years (from once vs twice daily randomization to 16 March 2012; maximum 2.6 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">1206</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Clinically Driven Monitoring (CDM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Laboratory plus Clinical Monitoring (LCM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A: abacavir (ABC)+lamivudine (3TC)+NNRTI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO non-nucleoside reverse transcriptase inhibitor (NNRTI): either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B:  ZDV+ABC+3TC+NNRTI-&gt;ABC+3TC+NNRTI maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C:  ZDV+ABC+3TC+NNRTI-&gt;ZDV+ABC+3TC maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Once-daily ABC+3TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABC [abacavir]: syrup or tablet, dosed once-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed once-daily according to weight-bands following WHO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twice-daily ABC+3TC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continued cotrimoxazole prophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once-daily doses 5-&lt;15 kg: 200 mg of trimethoprim + 40 mg sulfamethoxazole 15-&lt;30 kg: 400 mg trimethoprim + 80 mg sulfamethoxazole &gt;=30 kg: 800 mg trimethoprim + 160 mg sulfamethoxazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stopped cotrimoxazole prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children had been taking once-daily cotrimoxazole prophylaxis since at least ART initiation. Children randomised to this experimental arm stopped taking cotrimoxazole prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinically Driven Monitoring (CDM)</intervention_name>
    <description>Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. Screening results were used to assess eligibility. All subsequent results results at and after randomisation were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in a previous adult trial as were grade 4 laboratory toxicities (protocol safety criteria). Total lymphocytes and CD4 tests were never returned for CDM participants, but for all children other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.</description>
    <arm_group_label>Clinically Driven Monitoring (CDM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory plus Clinical Monitoring (LCM)</intervention_name>
    <description>Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. All results were returned to physicians for patient management. Other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.</description>
    <arm_group_label>Laboratory plus Clinical Monitoring (LCM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm A: ABC+3TC+NNRTI</intervention_name>
    <description>Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.</description>
    <arm_group_label>Arm A: abacavir (ABC)+lamivudine (3TC)+NNRTI</arm_group_label>
    <other_name>ABC: abacavir: Ziagen</other_name>
    <other_name>3TC: lamivudine: Epivir</other_name>
    <other_name>ABC+3TC co-formulated: Kivexa</other_name>
    <other_name>NVP: nevirapine, Viramune</other_name>
    <other_name>EFV: efavirenz, Sustiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm B:  ZDV+ABC+3TC+NNRTI-&gt;ABC+3TC+NNRTI maintenance</intervention_name>
    <description>Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.</description>
    <arm_group_label>Arm B:  ZDV+ABC+3TC+NNRTI-&gt;ABC+3TC+NNRTI maintenance</arm_group_label>
    <other_name>ZDV: zidovudine, azidothymidine, Retrovir</other_name>
    <other_name>ABC: abacavir: Ziagen</other_name>
    <other_name>3TC: lamivudine: Epivir</other_name>
    <other_name>ZDV+3TC co-formulated: Combivir</other_name>
    <other_name>ABC+3TC co-formulated: Kivexa</other_name>
    <other_name>ZDV+ABC+3TC co-formulated: Trizivir</other_name>
    <other_name>NVP: nevirapine, Viramune</other_name>
    <other_name>EFV: efavirenz, Sustiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm C:  ZDV+ABC+3TC+NNRTI-&gt;ZDV+ABC+3TC maintenance</intervention_name>
    <description>Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus zidovudine subsequently (triple NRTI maintenance). The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.</description>
    <arm_group_label>Arm C:  ZDV+ABC+3TC+NNRTI-&gt;ZDV+ABC+3TC maintenance</arm_group_label>
    <other_name>ZDV: zidovudine, azidothymidine, Retrovir</other_name>
    <other_name>ABC: abacavir: Ziagen</other_name>
    <other_name>3TC: lamivudine: Epivir</other_name>
    <other_name>ZDV+3TC co-formulated: Combivir</other_name>
    <other_name>ABC+3TC co-formulated: Kivexa</other_name>
    <other_name>ZDV+ABC+3TC co-formulated: Trizivir</other_name>
    <other_name>NVP: nevirapine, Viramune</other_name>
    <other_name>EFV: efavirenz, Sustiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Once-daily ABC+3TC</intervention_name>
    <arm_group_label>Once-daily ABC+3TC</arm_group_label>
    <other_name>ABC: abacavir: Ziagen</other_name>
    <other_name>3TC: lamivudine: Epivir</other_name>
    <other_name>ABC+3TC co-formulated: Kivexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Twice-daily ABC+3TC</intervention_name>
    <arm_group_label>Twice-daily ABC+3TC</arm_group_label>
    <other_name>ABC: abacavir: Ziagen</other_name>
    <other_name>3TC: lamivudine: Epivir</other_name>
    <other_name>ABC+3TC co-formulated: Kivexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continued cotrimoxazole prophylaxis</intervention_name>
    <arm_group_label>Continued cotrimoxazole prophylaxis</arm_group_label>
    <other_name>trimethoprim+sulfamethoxazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stopped cotrimoxazole prophylaxis</intervention_name>
    <arm_group_label>Stopped cotrimoxazole prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For initial randomisation to CDM vs LCM, and to ART induction strategy:

        Inclusion Criteria:

          1. Children should have an adult carer in the household who is either:

               -  participating in the DART trial  OR

               -  being treated with ART  OR

               -  HIV positive but not yet needing treatment but with access to a treatment
                  programme when ART is required  OR

               -  HIV negative. Children of DART participants should have first priority on any
                  available remaining slots to enter ARROW.

          2. Parents or guardians, and children where appropriate according to age and knowledge
             of HIV status, must be willing and able to give informed consent for randomisation to
             CDM or LCM and to first-line ART strategy.

          3. Participants must have a confirmed documented diagnosis of HIV-1 infection:

               1. For children aged under 18 months: two separate peripheral blood specimens from
                  different days, both results being positive with HIV-DNA polymerase chain
                  reaction (PCR).

               2. For children aged 18 months or over: antibody positive serology by ELISA test
                  (confirmed by licensed second ELISA or Western Blot) or WHO approved rapid test
                  (performed in series) both on the same sample.  Any child previously tested at
                  another clinic should have a repeat test at an ARROW screening laboratory to
                  confirm their status.

          4. Age 3 months to 17 years (13-17 years to be capped at 10%)

          5. ART na√Øve (except for exposure to perinatal ART for the prevention of mother-to-child
             HIV transmission).

          6. Meeting criteria for requiring ART according to WHO stage and CD4 percent or count:

               -  WHO paediatric clinical stage IV disease: treat regardless of CD4 percent or
                  count

               -  WHO paediatric clinical stage III disease:

                    -  &lt;12 months: treat all

                    -  &gt;12 months: treat all children irrespective of the CD4 percent or count;
                       however, in children aged &gt; 12 months with tuberculosis, lymphocytic
                       interstitial pneumonia (LIP), oral hairy leukoplakia (OHP) or
                       thrombocytopenia  (low platelet count treat) be guided by CD4 cell assays
                       (see below).

               -  WHO paediatric clinical stage II or I disease: treat guided by CD4 percent or
                  count

                    -  CD4%&lt;25% for infants &lt;12 months;

                    -  CD4%&lt;20% for children 1-&lt;3 years;

                    -  CD4% &lt;15% for children 3-&lt;5years;

                    -  CD4% &lt;15% for children &gt; 5years (consideration should also be taken of the
                       CD4 count. A CD4 count &lt;200 cells/mm3 can be used to guide starting ART and
                       CD4 should generally be &lt;350 cells/mm3.)

        Exclusion Criteria:

          1. Cannot, or unlikely to attend regularly (e.g. usual residence too far from study
             centre)

          2. Likelihood of poor adherence

          3. Presence of acute infection (e.g. malaria, helminthiasis, acute hepatitis, acute
             pneumonia, septicaemia, meningitis). Children may be admitted after recovery of an
             acute infection. Children with chronic lung disease, including recurrent respiratory
             infections, are eligible. Children with tuberculosis (TB) will not be enrolled while
             on the intensive phase of anti-tuberculosis therapy, but should be re-evaluated after
             the intensive phase and a decision made then about starting ART (see 4 below)

          4. In receipt of medication contraindicated by ART

               -  children under three years of age receiving anti-tuberculosis therapy should not
                  be enrolled (as they will have to receive nevirapine).

               -  on chemotherapy for malignancy

          5. Laboratory abnormalities which are a contra-indication for the child to start ART
             (haemoglobin &lt;8.5g/dL; neutrophils &lt;0.50x109/L; aspartate transaminase (AST) or
             alanine transaminase (ALT) &gt;5 x the upper limit of normal (ULN); grade 3 renal
             dysfunction - creatinine &gt;1.9 x ULN).

             N.B. causes of anaemia, such as concurrent bacterial infection, malaria,
             helminthiasis and/or malnutrition should be investigated, and treatment for anaemia
             and its causes commenced prior to re-screening for eligibility.

          6. Being pregnant or breast-feeding an infant

          7. Perinatal exposure to nevirapine (either through prevention of mother-to-child
             transmission (pMTCT) or breastfeeding) for children aged 3 - 6 months only

        Eligibility criteria for the secondary randomisation to once vs twice daily
        lamivudine+abacavir Inclusion criteria

          1. Participating in ARROW

          2. On ART for at least 36 weeks

          3. Currently taking lamivudine+abacavir twice daily as part of their ART regimen and
             expected to stay on these two drugs for at least the next 12 weeks

          4. Parents or guardians, and children where appropriate according to age and knowledge
             of HIV status, must be willing and able to give informed consent for randomisation to
             once or twice daily lamivudine+abacavir

             Exclusion criteria

          5. Likely to switch to second-line therapy in the next 12 weeks

        Eligibility criteria for the secondary randomisation to stop or continue cotrimoxazole
        prophylaxis randomisation Inclusion criteria

          1. Participating in ARROW

          2. Aged at least 3 years

          3. Initiated ART at least 96 weeks previously, and received at least 96 weeks of ART
             allowing for any interruptions in ART

          4. Currently prescribed daily cotrimoxazole as primary prophylaxis

          5. Parents or guardians, and children where appropriate according to age and knowledge
             of HIV status, must be willing and able to give informed consent for randomisation to
             stop or continue daily cotrimoxazole prophylaxis

          6. If living in a malaria endemic area, has an insecticide treated bednet and prepared
             to use this for the child.

             Exclusion criteria

          7. Previous diagnosis of Pneumocystis jiroveci pneumonia (cotrimoxazole is secondary
             prophylaxis and should not be discontinued)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana M Gibb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Research Council</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Mugyenyi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joint Clinical Research Centre, Kampala, Uganda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kusum Nathoo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zimbabwe, Harare, Zimbabwe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adeodata Kekitiinwa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine Children's Foundation, Mulago, Uganda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paula Munderi, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>MRC /UVRI Uganda Research Unit on AIDS, Entebbe, Uganda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor Musiime, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joint Clinical Research Centre, Kampala, Uganda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mutsa F Bwakura-Dangarembizi, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zimbabwe, Harare, Zimbabwe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippa Musoke, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine Children's Foundation, Mulago, Uganda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabrina Bakeera-Kitaka, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine Children's Foundation, Mulago, Uganda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Nahirya-Ntege, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>MRC/UVRI Uganda Research Unit on Aids</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MRC /UVRI Uganda Research Unit on AIDS</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Clinical Research Centre</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine Children's Foundation</name>
      <address>
        <city>Mulago</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe Medical School</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
    <country>Zimbabwe</country>
  </location_countries>
  <link>
    <url>http://www.arrowtrial.org/</url>
    <description>main ARROW trial webpage</description>
  </link>
  <results_reference>
    <citation>ARROW Trial team, Kekitiinwa A, Cook A, Nathoo K, Mugyenyi P, Nahirya-Ntege P, Bakeera-Kitaka S, Thomason M, Bwakura-Dangarembizi M, Musiime V, Munderi P, Naidoo-James B, Vhembo T, Tumusiime C, Katuramu R, Crawley J, Prendergast AJ, Musoke P, Walker AS, Gibb DM. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013 Apr 20;381(9875):1391-403. doi: 10.1016/S0140-6736(12)62198-9. Epub 2013 Mar 7.</citation>
    <PMID>23473847</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 4, 2014</lastchanged_date>
  <firstreceived_date>December 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Research Council</investigator_affiliation>
    <investigator_full_name>Diana M Gibb</investigator_full_name>
    <investigator_title>Professor of Epidemiology</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Africa</keyword>
  <keyword>children</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>laboratory monitoring</keyword>
  <keyword>toxicity</keyword>
  <keyword>CD4</keyword>
  <keyword>induction maintenance</keyword>
  <keyword>cotrimoxazole</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>abacavir</keyword>
  <keyword>lamivudine</keyword>
  <keyword>once daily</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim-Sulfamethoxazole Combination</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
